Articles
-
6 days ago |
insights.citeline.com | Lisa Takagi |Joseph Haas |Anju Ghangurde |Vibha Ravi
Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding PlatformPlus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.
-
2 weeks ago |
insights.citeline.com | Lisa Takagi
Japan Identifies Drugs ‘In Urgent Need’ Of Development14 Products On ‘A List’ Artesunate for malaria, TB drug pretomanid and omadacycline for pneumonia and skin infections are among the drugs identified by Japanese regulatory authorities in urgent need of domestic development. Japan shifts towards more active in addressing drug gap through its policies. (Shutterstock)
-
3 weeks ago |
insights.citeline.com | Lisa Takagi
Japan Pushes Generic Industry Reforms Via New Govt FundEnd To ‘Small Volume, High Mix’ EyedAmid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.
-
3 weeks ago |
insights.citeline.com | Joseph Haas |Lisa Takagi
Asia Deal Watch: Dr. Reddy’s Gets Regional Rights To Pair Of Bio-Thera BiosimilarsPlus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
-
1 month ago |
insights.citeline.com | Lisa Takagi
Japan T-Reg Venture RegCell Raises New Funds, Relocates To USLead Therapy Into Clinic This Year Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding. A Japanese cell therapy venture RegCell relocated its HQ from Japan to US with $48.5m financing. (Shutterstock)
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- Tweets
- DMs Open
CPHI Japan 2025 has @ScripIanHaydock presenting global R&D trends from Citeline. Cancer remains at the top focus with Chinese firms’ growing presence. https://t.co/rHWePdqVXv
Trump’s US FDA Takeover Similar To Flat Earth Proponents Running NASA, Woodcock Says https://t.co/AAaHxmLRWa
RT @ScripIanHaydock: A look at the view from the India #pharma perspective, by @scripvibha for @PharmaScrip #tariffs Trump Tariffs – Indi…